FEED

+ Watchlist + Portfolio

ENvue Medical, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.42
52-Week Range: $0.29 – $17.40
Market Cap: $3.74M
P/E (TTM): —
EPS (TTM): -25.22
Dividend Yield: —

Advanced Metrics

Price/Book: 0.05
PEG Ratio: —
Return on Equity: -59.14%
Return on Assets: -20.99%
Gross Margin: -26.06%
Operating Margin: -2290.38%
Profit Margin: 0.00%
Current Ratio: 0.66
Debt/Equity: 0.04
Total Debt: $1.31M
Free Cash Flow: $-7.87M
Revenue Growth: -51.60%
Earnings Growth: —
Enterprise Value: $4.92M

FEED Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$752.00K	$2.28M	$2.56M	$2.55M
Cost of Revenue	$585.00K	$746.00K	$1.05M	$2.40M
Gross Profit	$167.00K	$1.54M	$1.51M	$153.00K
Research & Development	$283.00K	$185.00K	$909.00K	$1.76M
Selling, General & Admin	$4.90M	$4.79M	$4.18M	$10.13M
Operating Expenses	$5.18M	$4.97M	$5.09M	$11.89M
Operating Income	-$5.01M	-$3.44M	-$3.58M	-$11.73M
EBITDA	-$5.07M	-$3.55M	-$3.58M	-$10.84M
Pretax Income	-$5.41M	-$3.68M	-$3.69M	-$18.49M
Income Tax	$35.00K	$29.00K	$19.00K	-$307.00K
Net Income	-$5.45M	-$3.71M	-$3.71M	-$18.18M
Diluted EPS	-422.40	-233.20	-137.30	-26.69
Diluted Shares	12906	15910	26985	628534

FEED Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.71M	$3.28M	$752.00K	$4.22M
Receivables	$109.00K	$425.00K	$268.00K	$543.00K
Inventory	$2.17M	$2.73M	$2.19M	$2.34M
Current Assets	$5.61M	$6.49M	$3.33M	$7.27M
Total Assets	$5.88M	$6.67M	$3.63M	$41.12M
Current Liabilities	$2.32M	$2.45M	$2.72M	$6.66M
Total Debt	$81.00K	$5.00K	$116.00K	$1.20M
Total Liabilities	$2.65M	$2.69M	$3.00M	$7.63M
Retained Earnings	-$62.38M	-$66.10M	-$69.80M	-$90.48M
Shareholders' Equity	$3.23M	$3.99M	$627.00K	$33.50M
Working Capital	$3.29M	$4.03M	$609.00K	$611.00K

FEED Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.04M	-$3.60M	-$2.52M	-$9.37M
Capital Expenditure	-$3.00K	-$1.00K	-$3.00K	-$60.00K
Free Cash Flow	-$7.04M	-$3.60M	-$2.52M	-$9.43M
Depreciation & Amortisation	$1.00K	$1.00K	$1.00K	$897.00K
Stock-Based Compensation	$354.00K	$293.00K	$356.00K	$0.00
Investing Cash Flow	-$3.00K	-$1.00K	-$3.00K	$88.00K
Financing Cash Flow	$2.09M	$4.22M	$1.00K	$12.79M
Share Repurchases	—	—	$0.00	-$5.00M
Net Change in Cash	-$4.95M	$619.00K	-$2.52M	$3.50M

FEED Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.02M	$494.00K	$722.00K	$312.00K	$653.00K
Cost of Revenue	$656.00K	$529.00K	$533.00K	$682.00K	$708.00K
Gross Profit	$369.00K	-$35.00K	$189.00K	-$370.00K	-$55.00K
Research & Development	$530.00K	$972.00K	$221.00K	$39.00K	$468.00K
Selling, General & Admin	$1.69M	$2.97M	$2.21M	$3.25M	$3.19M
Operating Expenses	$2.22M	$3.94M	$2.44M	$3.29M	$3.66M
Operating Income	-$1.85M	-$3.98M	-$2.25M	-$3.66M	-$3.71M
EBITDA	-$1.79M	-$3.40M	$855.00K	-$6.51M	-$3.54M
Pretax Income	-$1.86M	-$3.91M	$545.00K	-$13.27M	-$3.79M
Income Tax	$15.00K	$62.00K	$35.00K	-$419.00K	$33.00K
Net Income	-$1.87M	-$3.97M	$510.00K	-$12.85M	-$3.82M
Diluted EPS	-29.90	-10.30	-0.91	—	-6.88
Diluted Shares	62615	48456	858434	—	3.29M

FEED Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$601.00K	$4.03M	$6.95M	$4.22M	$2.23M
Receivables	$1.24M	$626.00K	$792.00K	$543.00K	$725.00K
Inventory	$2.02M	$2.21M	$2.24M	$2.34M	$2.27M
Current Assets	$3.86M	$6.89M	$10.02M	$7.27M	$6.20M
Total Assets	$44.10M	$51.48M	$54.38M	$41.12M	$39.87M
Current Liabilities	$8.20M	$6.54M	$11.64M	$6.66M	$6.87M
Total Debt	$3.92M	$2.13M	$3.17M	$1.20M	$1.21M
Total Liabilities	$8.43M	$11.01M	$11.92M	$7.63M	$7.86M
Retained Earnings	-$72.30M	-$75.99M	-$76.86M	-$90.48M	-$112.14M
Shareholders' Equity	$35.67M	$40.48M	$42.46M	$33.50M	$32.02M
Working Capital	-$4.34M	$349.00K	-$1.63M	$611.00K	-$668.00K
Net Debt	$3.15M	—	—	—	—

FEED Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.34M	-$3.38M	-$1.97M	-$2.68M	-$4.31M
Capital Expenditure	-$5.00K	-$4.00K	-$28.00K	-$23.00K	-$17.00K
Free Cash Flow	-$1.35M	-$3.39M	-$2.00M	-$2.70M	-$4.33M
Depreciation & Amortisation	$18.00K	$364.00K	$257.00K	$258.00K	$217.00K
Stock-Based Compensation	$0.00	$0.00	$0.00	$0.00	—
Investing Cash Flow	$143.00K	-$4.00K	-$28.00K	-$23.00K	-$17.00K
Financing Cash Flow	$1.05M	$6.85M	$4.92M	-$34.00K	$2.34M
Share Repurchases	$0.00	—	—	$0.00	-$1.56M
Net Change in Cash	-$150.00K	$3.46M	$2.92M	-$2.73M	-$1.99M

Market Snapshot

About

ENvue Medical, Inc. is a medical device company developing innovative solutions for urological and gynecological applications. The company's product portfolio includes devices for female pelvic floor disorders and urinary incontinence treatment. ENvue Medical's proprietary technologies aim to provide minimally invasive treatment options that improve patient outcomes and quality of life. The company focuses on clinical validation through trials and regulatory approvals to support commercialization. Strategic priorities include expanding the product pipeline and building commercial infrastructure for market penetration.